Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol

Ottaiano, Alessandro; Scala, Stefania; Normanno, Nicola; Napolitano, Maria; Capozzi, Monica; Rachiglio, Anna Maria; Roma, Cristin; Trotta, Anna Maria; D’Alterio, Crescenzo; Portella, Luigi; Romano, Carmela; Cassata, Antonino; Casaretti, Rossana; Silvestro, Lucrezia; Nappi, Anna; Tafuto, Salvatore; Avallone, Antonio; De Stefano, Alfonso; Tamburini, Mario; Picone, Carmine; Petrillo, Antonella; Izzo, Francesco; Palaia, Raffaele; Albino, Vittorio; Amore, Alfonso; Belli, Andrea; Pace, Ugo; Di Marzo, Massimiliano; Chiodini, Paolo; Botti, Gerardo; De Feo, Gianfranco; Delrio, Paolo; Nasti, Guglielmo

doi:10.1186/s12885-019-6109-z

BMC Cancer

Article metrics
Last updated: Wed, 25 Sep 2024 1:56:37 Z

Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol

Access & Citations

3761

Article Accesses
9

Web of Science
9

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com